Detailed Narrative
Q2 FY26 Performance Overview
Emcure Pharmaceuticals reported a robust Q2 FY26, with revenues from operations growing 13.4% year-on-year to INR 2,270 crores. The company achieved its highest quarterly Profit After Tax (PAT) of INR 251 crores, reflecting a 24% YoY increase. EBITDA, excluding other income, rose 15.2% YoY to INR 439 crores, with the EBITDA margin improving to 19.3% from 19% in Q2 FY25, driven by operating leverage and productivity gains.
Novo Nordisk Partnership and Semaglutide Strategy
A significant strategic move in the quarter was the exclusive partnership with Novo Nordisk to distribute semaglutide (Poviztra) in India. Management highlighted the substantial potential in the GLP market, given India's large obese/overweight population (250-350 million). This partnership provides an early entry into the obesity market, positioning Emcure to shape it, leveraging Novo's extensive clinical data and Emcure's strong distribution network and field force.
Domestic Business Traction and Zuventus Consolidation
The domestic business demonstrated strong traction, growing 10.6% YoY to INR 1,031 crores, outperforming the industry. Growth was observed across key segments like gynecology and cardiology, with new areas such as derma, consumer, and diabetes also performing well. The company completed the acquisition of the remaining minority stake in Zuventus, enabling full consolidation and anticipating future back-end synergies to further drive growth above industry averages.
International Segment Growth Drivers
The international segment delivered strong growth of 15.8% YoY, reaching INR 1,238 crores. Europe was a key driver, growing 22.7% YoY, primarily due to the ramp-up of Amphotericin B and benefits from the Manx acquisition. Canada also saw healthy growth of 17.5%, fueled by market share gains and new launches. The Rest of the World business grew in teens, largely led by the non-ARV segment, with good product pipeline visibility for future growth.
Margin Expansion and Debt Management
Gross margins for the quarter stood at 60.8%, slightly up from 60.6% in Q2 FY25, attributed to product and business mix. The company aims to improve its base EBITDA margins by 150 basis points for the full year. Net debt for the quarter was INR 837 crores, an increase due to the partial payout for the Zuventus stake. Management revised its debt-free target to the end of next year (18-24 months) from the previously guided FY26, acknowledging the impact of the acquisition.
R&D and Biosimilar Pipeline Progress
Emcure continues to invest in internal R&D efforts and partnerships with MNCs. In the biosimilar space, the company completed Phase III of Bevacizumab and expects to submit the file for evaluation by the SEC and regulatory approval in the next few weeks. This progress, along with a pipeline of complex injectables and biosimilars for emerging markets, underscores the company's focus on leveraging its manufacturing capabilities for future growth.